WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406117
Description: SN-28049 SN is a DNA intercalating drug that binds selectively to GC-rich DNA and shows curative activity against the Colon 38 adenocarcinoma in mice. SN 28049 has a complex action that may involve poisoning of topo IIalpha, suppression of topo I and inhibition of gene transcription from promoters with SP-1 sites. These actions may contribute to the promising experimental solid tumour anticancer activity of SN 28049.
MedKoo Cat#: 406117
Chemical Formula: C19H22N4O2
Exact Mass: 338.17428
Molecular Weight: 338.4
Elemental Analysis: C, 67.44; H, 6.55; N, 16.56; O, 9.46
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SN28049; SN28049; SN 28049
IUPAC/Chemical Name: N-(2-(dimethylamino)ethyl)-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b][1,6]naphthyridine-4-carboxamide
InChi Key: CSMRPIFORJZYCJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H22N4O2/c1-12-6-5-7-13-10-14-17(21-16(12)13)15(11-23(4)19(14)25)18(24)20-8-9-22(2)3/h5-7,10-11H,8-9H2,1-4H3,(H,20,24)
SMILES Code: O=C(C1=CN(C)C(C2=CC3=CC=CC(C)=C3N=C12)=O)NCCN(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 338.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lukka PB, Paxton JW, Kestell P, Baguley BC. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemother Pharmacol. 2012 Jul;70(1):151-60. doi: 10.1007/s00280-012-1892-0. Epub 2012 Jun 3. PubMed PMID: 22660735.
2: Lukka PB, Paxton JW, Atwell GJ, Kestell P, Baguley BC. A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. J Pharm Biomed Anal. 2012 Apr 7;63:9-16. doi: 10.1016/j.jpba.2012.01.022. Epub 2012 Jan 28. PubMed PMID: 22361659.
3: Chen YY, Finlay GJ, Kirker JA, Marshall ES, Richardson E, Baguley BC. In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma. Invest New Drugs. 2011 Dec;29(6):1504-10. doi: 10.1007/s10637-010-9509-0. Epub 2010 Aug 10. PubMed PMID: 20697772.
4: Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs. 2011 Oct;29(5):1102-10. doi: 10.1007/s10637-010-9473-8. Epub 2010 Jun 22. PubMed PMID: 20567995.
5: Lukka PB, Paxton JW, Kestell P, Baguley BC. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol. 2010 May;65(6):1145-52. doi: 10.1007/s00280-009-1123-5. Epub 2009 Sep 23. PubMed PMID: 19774378.
6: Lukka PB, Kestell P, Paxton JW, Baguley BC. Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridi ne-4-carboxamide (SN 28049). J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):368-72. doi: 10.1016/j.jchromb.2008.09.023. Epub 2008 Sep 26. PubMed PMID: 18926778.
7: Bridewell DJ, Porter AC, Finlay GJ, Baguley BC. The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol. 2008 Oct;62(5):753-62. doi: 10.1007/s00280-007-0660-z. Epub 2008 Jan 3. PubMed PMID: 18175117.